| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mucocutaneous Lymph Node Syndrome | 141 | 2024 | 537 | 19.380 |
Why?
|
| Heart Defects, Congenital | 148 | 2024 | 4673 | 9.510 |
Why?
|
| Coronary Aneurysm | 42 | 2023 | 231 | 7.450 |
Why?
|
| Transposition of Great Vessels | 41 | 2023 | 590 | 6.000 |
Why?
|
| Hypoplastic Left Heart Syndrome | 31 | 2023 | 594 | 5.000 |
Why?
|
| Norwood Procedures | 21 | 2023 | 192 | 4.890 |
Why?
|
| Immunoglobulins, Intravenous | 50 | 2023 | 664 | 4.880 |
Why?
|
| Cardiac Surgical Procedures | 63 | 2024 | 3603 | 3.300 |
Why?
|
| Fontan Procedure | 27 | 2023 | 791 | 3.270 |
Why?
|
| Developmental Disabilities | 32 | 2024 | 1504 | 3.270 |
Why?
|
| Blalock-Taussig Procedure | 7 | 2022 | 60 | 3.060 |
Why?
|
| Systemic Inflammatory Response Syndrome | 23 | 2024 | 621 | 2.960 |
Why?
|
| Cardiopulmonary Bypass | 37 | 2020 | 1093 | 2.480 |
Why?
|
| Heart Ventricles | 26 | 2023 | 3806 | 2.250 |
Why?
|
| Tetralogy of Fallot | 13 | 2023 | 631 | 2.200 |
Why?
|
| Cardiology | 19 | 2022 | 1667 | 2.020 |
Why?
|
| Coronary Vessels | 26 | 2024 | 3072 | 1.990 |
Why?
|
| Child | 275 | 2024 | 79813 | 1.950 |
Why?
|
| Infant | 193 | 2024 | 36054 | 1.930 |
Why?
|
| Child Development | 27 | 2023 | 2285 | 1.580 |
Why?
|
| Child, Preschool | 172 | 2024 | 42058 | 1.550 |
Why?
|
| Social Class | 7 | 2023 | 1999 | 1.540 |
Why?
|
| Fever | 15 | 2023 | 1617 | 1.500 |
Why?
|
| Echocardiography | 44 | 2022 | 4962 | 1.460 |
Why?
|
| Heart Diseases | 25 | 2022 | 2782 | 1.460 |
Why?
|
| Anti-Inflammatory Agents | 6 | 2017 | 1793 | 1.370 |
Why?
|
| Pulmonary Artery | 16 | 2023 | 1916 | 1.300 |
Why?
|
| Infant, Newborn | 109 | 2024 | 26182 | 1.240 |
Why?
|
| Hypothermia, Induced | 17 | 2017 | 756 | 1.240 |
Why?
|
| Hemodilution | 7 | 2014 | 120 | 1.220 |
Why?
|
| Coronary Vessel Anomalies | 10 | 2023 | 308 | 1.210 |
Why?
|
| Humans | 524 | 2024 | 758381 | 1.200 |
Why?
|
| Pediatrics | 19 | 2020 | 3587 | 1.090 |
Why?
|
| Heart Arrest, Induced | 11 | 2011 | 357 | 1.080 |
Why?
|
| Immunologic Factors | 11 | 2020 | 1585 | 1.070 |
Why?
|
| Nervous System | 7 | 2020 | 543 | 1.070 |
Why?
|
| Adolescent | 150 | 2024 | 87888 | 1.050 |
Why?
|
| Quality of Life | 27 | 2024 | 13286 | 0.990 |
Why?
|
| Executive Function | 14 | 2024 | 1375 | 0.980 |
Why?
|
| Male | 283 | 2024 | 358742 | 0.920 |
Why?
|
| Female | 284 | 2024 | 390316 | 0.920 |
Why?
|
| Myocarditis | 6 | 2022 | 766 | 0.900 |
Why?
|
| Thoracic Surgery | 7 | 2021 | 722 | 0.850 |
Why?
|
| Risk Factors | 94 | 2024 | 73806 | 0.820 |
Why?
|
| Brain | 31 | 2024 | 26951 | 0.800 |
Why?
|
| Postoperative Complications | 35 | 2023 | 15638 | 0.780 |
Why?
|
| Length of Stay | 24 | 2022 | 6439 | 0.780 |
Why?
|
| Ventricular Function, Right | 6 | 2023 | 609 | 0.740 |
Why?
|
| Neuropsychological Tests | 31 | 2021 | 7023 | 0.740 |
Why?
|
| Endocarditis, Bacterial | 13 | 2012 | 442 | 0.710 |
Why?
|
| Treatment Outcome | 88 | 2024 | 64379 | 0.700 |
Why?
|
| Brain Injuries | 3 | 2023 | 2044 | 0.700 |
Why?
|
| Connective Tissue Diseases | 4 | 2023 | 285 | 0.680 |
Why?
|
| Hematocrit | 6 | 2010 | 627 | 0.660 |
Why?
|
| Follow-Up Studies | 60 | 2023 | 39060 | 0.660 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 4 | 2023 | 298 | 0.650 |
Why?
|
| Cognition Disorders | 8 | 2015 | 3975 | 0.650 |
Why?
|
| Retrospective Studies | 91 | 2024 | 80170 | 0.650 |
Why?
|
| Ventricular Dysfunction | 2 | 2017 | 144 | 0.630 |
Why?
|
| Fetus | 5 | 2022 | 1860 | 0.630 |
Why?
|
| Bioethical Issues | 1 | 2019 | 121 | 0.620 |
Why?
|
| Platelet Aggregation Inhibitors | 6 | 2020 | 2747 | 0.610 |
Why?
|
| Educational Status | 4 | 2020 | 2513 | 0.610 |
Why?
|
| Psychomotor Disorders | 4 | 2014 | 149 | 0.610 |
Why?
|
| Pandemics | 9 | 2022 | 8611 | 0.600 |
Why?
|
| Aortic Valve Stenosis | 8 | 2023 | 2002 | 0.590 |
Why?
|
| Hemodynamics | 11 | 2020 | 4159 | 0.590 |
Why?
|
| Biomedical Research | 7 | 2018 | 3417 | 0.570 |
Why?
|
| Time Factors | 53 | 2021 | 39873 | 0.570 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 3076 | 0.570 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 3196 | 0.560 |
Why?
|
| Bioprosthesis | 2 | 2019 | 591 | 0.550 |
Why?
|
| Pericardium | 2 | 2019 | 674 | 0.550 |
Why?
|
| Residence Characteristics | 4 | 2020 | 2058 | 0.550 |
Why?
|
| Risk Assessment | 35 | 2024 | 23883 | 0.550 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 6 | 2020 | 3701 | 0.550 |
Why?
|
| Thrombosis | 8 | 2023 | 2929 | 0.540 |
Why?
|
| Aspirin | 21 | 2021 | 3132 | 0.530 |
Why?
|
| American Heart Association | 14 | 2024 | 1039 | 0.530 |
Why?
|
| Prosthesis Failure | 2 | 2019 | 1198 | 0.520 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2020 | 1870 | 0.510 |
Why?
|
| Echocardiography, Doppler | 2 | 2019 | 898 | 0.510 |
Why?
|
| Heart Transplantation | 15 | 2024 | 3220 | 0.500 |
Why?
|
| Memory, Short-Term | 2 | 2020 | 979 | 0.500 |
Why?
|
| Health Status | 9 | 2020 | 4069 | 0.500 |
Why?
|
| Receptors, IgG | 3 | 2012 | 559 | 0.490 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2017 | 306 | 0.490 |
Why?
|
| Boston | 22 | 2021 | 9304 | 0.490 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2018 | 615 | 0.490 |
Why?
|
| Aftercare | 9 | 2023 | 910 | 0.480 |
Why?
|
| Oximetry | 4 | 2010 | 460 | 0.480 |
Why?
|
| Pericardiectomy | 1 | 2014 | 46 | 0.480 |
Why?
|
| Glucocorticoids | 8 | 2023 | 2144 | 0.480 |
Why?
|
| Placenta | 1 | 2024 | 1702 | 0.480 |
Why?
|
| Methylprednisolone | 3 | 2007 | 384 | 0.470 |
Why?
|
| Pericardiocentesis | 1 | 2014 | 78 | 0.470 |
Why?
|
| Case-Control Studies | 26 | 2021 | 22031 | 0.470 |
Why?
|
| Leukoencephalopathies | 2 | 2018 | 249 | 0.470 |
Why?
|
| Cardiovascular Surgical Procedures | 3 | 2012 | 190 | 0.470 |
Why?
|
| Mentors | 2 | 2019 | 660 | 0.470 |
Why?
|
| Palliative Care | 7 | 2023 | 3570 | 0.460 |
Why?
|
| Age Factors | 25 | 2021 | 18357 | 0.460 |
Why?
|
| Macrophage Activation Syndrome | 4 | 2024 | 123 | 0.460 |
Why?
|
| United States | 66 | 2024 | 72140 | 0.460 |
Why?
|
| Decision Support Techniques | 5 | 2020 | 1996 | 0.450 |
Why?
|
| Parents | 11 | 2024 | 3548 | 0.450 |
Why?
|
| Thrombophilia | 2 | 2021 | 304 | 0.440 |
Why?
|
| Fellowships and Scholarships | 3 | 2016 | 1116 | 0.440 |
Why?
|
| Magnetic Resonance Imaging | 30 | 2024 | 36285 | 0.440 |
Why?
|
| Warfarin | 4 | 2021 | 1482 | 0.440 |
Why?
|
| Coronary Thrombosis | 5 | 2016 | 440 | 0.440 |
Why?
|
| Abnormalities, Multiple | 4 | 2012 | 1414 | 0.430 |
Why?
|
| Pericarditis | 1 | 2014 | 133 | 0.430 |
Why?
|
| Psychomotor Performance | 7 | 2014 | 1878 | 0.430 |
Why?
|
| Prospective Studies | 58 | 2024 | 54136 | 0.420 |
Why?
|
| Heart Valve Prosthesis | 3 | 2019 | 1466 | 0.420 |
Why?
|
| Autistic Disorder | 2 | 2019 | 1216 | 0.420 |
Why?
|
| Anticoagulants | 13 | 2023 | 4778 | 0.420 |
Why?
|
| Regenerative Medicine | 1 | 2016 | 307 | 0.420 |
Why?
|
| Survivors | 6 | 2023 | 2371 | 0.410 |
Why?
|
| Pericardial Effusion | 1 | 2014 | 247 | 0.410 |
Why?
|
| Prednisolone | 2 | 2012 | 326 | 0.410 |
Why?
|
| Learning | 2 | 2019 | 1739 | 0.410 |
Why?
|
| Cerebrovascular Circulation | 10 | 2019 | 2731 | 0.410 |
Why?
|
| Venous Thromboembolism | 5 | 2023 | 1855 | 0.400 |
Why?
|
| Predictive Value of Tests | 21 | 2023 | 15225 | 0.390 |
Why?
|
| Thoracic Arteries | 1 | 2011 | 40 | 0.390 |
Why?
|
| Delayed Diagnosis | 4 | 2021 | 463 | 0.390 |
Why?
|
| Electrocardiography | 9 | 2021 | 6363 | 0.390 |
Why?
|
| Nervous System Diseases | 7 | 2012 | 1647 | 0.390 |
Why?
|
| Aortic Valve | 2 | 2019 | 1950 | 0.380 |
Why?
|
| Codes of Ethics | 1 | 2011 | 61 | 0.370 |
Why?
|
| Premature Birth | 1 | 2023 | 1771 | 0.370 |
Why?
|
| Extracorporeal Membrane Oxygenation | 7 | 2024 | 1452 | 0.370 |
Why?
|
| Clinical Competence | 6 | 2019 | 4775 | 0.370 |
Why?
|
| Coronary Angiography | 10 | 2024 | 4451 | 0.370 |
Why?
|
| Mothers | 2 | 2022 | 2189 | 0.360 |
Why?
|
| Young Adult | 38 | 2024 | 58808 | 0.360 |
Why?
|
| Peptic Ulcer | 2 | 2024 | 217 | 0.360 |
Why?
|
| Renal Veins | 1 | 2011 | 102 | 0.360 |
Why?
|
| Hospitalization | 12 | 2023 | 10653 | 0.360 |
Why?
|
| Rheumatic Fever | 2 | 2007 | 75 | 0.360 |
Why?
|
| Incidence | 19 | 2022 | 21273 | 0.360 |
Why?
|
| Vascular Grafting | 1 | 2012 | 152 | 0.350 |
Why?
|
| Diffusion Tensor Imaging | 5 | 2017 | 2387 | 0.350 |
Why?
|
| Marketing of Health Services | 1 | 2011 | 150 | 0.350 |
Why?
|
| Prognosis | 27 | 2021 | 29558 | 0.350 |
Why?
|
| Hospital Mortality | 12 | 2024 | 5273 | 0.340 |
Why?
|
| Coronary Artery Disease | 8 | 2021 | 6363 | 0.340 |
Why?
|
| Health Expenditures | 2 | 2023 | 2348 | 0.340 |
Why?
|
| Coronary Stenosis | 3 | 2017 | 793 | 0.330 |
Why?
|
| Brain Damage, Chronic | 4 | 2012 | 267 | 0.330 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2019 | 1547 | 0.320 |
Why?
|
| Death, Sudden, Cardiac | 5 | 2014 | 1554 | 0.320 |
Why?
|
| Ventricular Function, Left | 8 | 2023 | 3858 | 0.320 |
Why?
|
| North America | 9 | 2019 | 1276 | 0.320 |
Why?
|
| Immunoglobulins | 1 | 2012 | 859 | 0.320 |
Why?
|
| Growth | 4 | 2016 | 365 | 0.310 |
Why?
|
| Longevity | 1 | 2016 | 1050 | 0.310 |
Why?
|
| Coronary Artery Bypass | 4 | 2016 | 2189 | 0.310 |
Why?
|
| Dilatation, Pathologic | 6 | 2013 | 527 | 0.310 |
Why?
|
| Cross-Sectional Studies | 26 | 2023 | 25953 | 0.310 |
Why?
|
| Heart | 10 | 2024 | 4382 | 0.310 |
Why?
|
| Reoperation | 8 | 2024 | 4282 | 0.300 |
Why?
|
| Health Status Disparities | 2 | 2019 | 1832 | 0.300 |
Why?
|
| Monitoring, Intraoperative | 4 | 2010 | 939 | 0.300 |
Why?
|
| Portal Vein | 1 | 2011 | 429 | 0.300 |
Why?
|
| Cognition | 7 | 2019 | 6955 | 0.300 |
Why?
|
| Stress, Psychological | 4 | 2019 | 4457 | 0.300 |
Why?
|
| Critical Illness | 4 | 2024 | 2703 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2021 | 10146 | 0.300 |
Why?
|
| Heart Septal Defects, Ventricular | 10 | 2008 | 491 | 0.300 |
Why?
|
| Mental Health Services | 1 | 2019 | 1718 | 0.290 |
Why?
|
| Cost of Illness | 2 | 2023 | 1936 | 0.290 |
Why?
|
| Drug Therapy, Combination | 9 | 2021 | 6293 | 0.290 |
Why?
|
| Vena Cava, Inferior | 1 | 2011 | 458 | 0.290 |
Why?
|
| Neurologic Examination | 10 | 2021 | 914 | 0.290 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 7 | 2018 | 2270 | 0.290 |
Why?
|
| Cardiology Service, Hospital | 5 | 2011 | 239 | 0.280 |
Why?
|
| Ventricular Function | 3 | 2023 | 406 | 0.280 |
Why?
|
| Nervous System Malformations | 2 | 2021 | 244 | 0.280 |
Why?
|
| Heart Failure | 9 | 2023 | 11594 | 0.280 |
Why?
|
| Evidence-Based Medicine | 11 | 2015 | 3671 | 0.280 |
Why?
|
| Genetic Predisposition to Disease | 14 | 2021 | 17768 | 0.280 |
Why?
|
| Critical Pathways | 5 | 2017 | 473 | 0.280 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 2359 | 0.270 |
Why?
|
| Immunization, Passive | 7 | 1994 | 616 | 0.270 |
Why?
|
| Proportional Hazards Models | 10 | 2020 | 12440 | 0.270 |
Why?
|
| Embolization, Therapeutic | 2 | 2018 | 1407 | 0.270 |
Why?
|
| Motor Skills Disorders | 2 | 2003 | 89 | 0.270 |
Why?
|
| Databases, Factual | 14 | 2022 | 7980 | 0.270 |
Why?
|
| Registries | 7 | 2022 | 8176 | 0.270 |
Why?
|
| Preoperative Care | 3 | 2011 | 2249 | 0.260 |
Why?
|
| Drug Resistance | 6 | 2019 | 1593 | 0.260 |
Why?
|
| Gestational Age | 6 | 2022 | 3565 | 0.260 |
Why?
|
| Thoracic Surgical Procedures | 3 | 2021 | 348 | 0.260 |
Why?
|
| Fibrinolytic Agents | 3 | 2020 | 2071 | 0.260 |
Why?
|
| Postoperative Period | 10 | 2018 | 1812 | 0.260 |
Why?
|
| gamma-Globulins | 8 | 1993 | 123 | 0.260 |
Why?
|
| Clinical Trials as Topic | 11 | 2023 | 7985 | 0.250 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 2714 | 0.250 |
Why?
|
| Infusions, Intravenous | 9 | 2017 | 2210 | 0.250 |
Why?
|
| Immunosuppressive Agents | 2 | 2017 | 4158 | 0.250 |
Why?
|
| Vascular Malformations | 1 | 2011 | 464 | 0.250 |
Why?
|
| Nerve Net | 2 | 2018 | 2263 | 0.250 |
Why?
|
| Hospitals, Pediatric | 7 | 2016 | 1854 | 0.240 |
Why?
|
| Patient Discharge | 9 | 2023 | 3433 | 0.240 |
Why?
|
| Apolipoprotein E2 | 2 | 2016 | 135 | 0.240 |
Why?
|
| Intelligence Tests | 8 | 2017 | 500 | 0.240 |
Why?
|
| Antibiotic Prophylaxis | 7 | 2012 | 642 | 0.240 |
Why?
|
| Spleen | 1 | 2011 | 2296 | 0.240 |
Why?
|
| C-Reactive Protein | 8 | 2023 | 3812 | 0.240 |
Why?
|
| Child Behavior Disorders | 4 | 2019 | 805 | 0.240 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2021 | 2115 | 0.240 |
Why?
|
| Patient Care Management | 4 | 2011 | 302 | 0.230 |
Why?
|
| Spectroscopy, Near-Infrared | 3 | 2019 | 739 | 0.230 |
Why?
|
| Antibodies, Monoclonal | 4 | 2010 | 9160 | 0.230 |
Why?
|
| Logistic Models | 12 | 2021 | 13276 | 0.230 |
Why?
|
| Oxygen | 7 | 2019 | 4192 | 0.230 |
Why?
|
| Acute Disease | 14 | 2021 | 7225 | 0.230 |
Why?
|
| Models, Neurological | 1 | 2012 | 1757 | 0.230 |
Why?
|
| Arrhythmias, Cardiac | 5 | 2024 | 2248 | 0.230 |
Why?
|
| Central Nervous System Stimulants | 2 | 2012 | 1176 | 0.230 |
Why?
|
| Carbon Dioxide | 3 | 2004 | 1146 | 0.230 |
Why?
|
| Cohort Studies | 23 | 2024 | 41252 | 0.230 |
Why?
|
| Linear Models | 10 | 2021 | 5861 | 0.230 |
Why?
|
| Myocardial Infarction | 6 | 2020 | 11424 | 0.230 |
Why?
|
| Postoperative Care | 6 | 2016 | 1471 | 0.230 |
Why?
|
| Pyridones | 2 | 2019 | 785 | 0.230 |
Why?
|
| Protein-Losing Enteropathies | 1 | 2023 | 45 | 0.220 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 2019 | 4342 | 0.220 |
Why?
|
| Health Services Accessibility | 4 | 2021 | 5403 | 0.220 |
Why?
|
| Circulatory Arrest, Deep Hypothermia Induced | 3 | 2017 | 82 | 0.220 |
Why?
|
| Achievement | 2 | 2016 | 289 | 0.220 |
Why?
|
| Body Temperature | 2 | 2004 | 777 | 0.220 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2010 | 1730 | 0.210 |
Why?
|
| Musculoskeletal Abnormalities | 1 | 2024 | 100 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2020 | 6493 | 0.210 |
Why?
|
| Single-Blind Method | 4 | 2019 | 1570 | 0.210 |
Why?
|
| Quality Indicators, Health Care | 4 | 2020 | 1797 | 0.210 |
Why?
|
| DNA Copy Number Variations | 4 | 2023 | 2012 | 0.210 |
Why?
|
| Recovery of Function | 5 | 2020 | 2971 | 0.210 |
Why?
|
| Immunomodulation | 3 | 2021 | 545 | 0.210 |
Why?
|
| Health Status Indicators | 2 | 2013 | 970 | 0.210 |
Why?
|
| Immunization | 2 | 2017 | 1227 | 0.200 |
Why?
|
| Ticlopidine | 2 | 2013 | 731 | 0.200 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 1547 | 0.200 |
Why?
|
| Prenatal Diagnosis | 4 | 2020 | 1264 | 0.200 |
Why?
|
| Respiration, Artificial | 3 | 2020 | 2618 | 0.200 |
Why?
|
| Aorta, Thoracic | 3 | 2021 | 1094 | 0.200 |
Why?
|
| Coronary Disease | 9 | 2007 | 5917 | 0.200 |
Why?
|
| Aortic Coarctation | 3 | 2020 | 282 | 0.200 |
Why?
|
| Diagnosis, Differential | 15 | 2021 | 12951 | 0.200 |
Why?
|
| Myocardial Contraction | 4 | 2014 | 1516 | 0.200 |
Why?
|
| Adult | 61 | 2024 | 219916 | 0.200 |
Why?
|
| Syndrome | 4 | 2021 | 3262 | 0.200 |
Why?
|
| Age Distribution | 4 | 2014 | 2882 | 0.200 |
Why?
|
| Magnetic Resonance Imaging, Cine | 4 | 2023 | 1044 | 0.190 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2020 | 342 | 0.190 |
Why?
|
| Medicaid | 3 | 2023 | 2807 | 0.190 |
Why?
|
| Perceptual Disorders | 1 | 2003 | 197 | 0.190 |
Why?
|
| Income | 3 | 2020 | 1872 | 0.190 |
Why?
|
| Algorithms | 13 | 2024 | 13959 | 0.190 |
Why?
|
| Probability | 6 | 2017 | 2467 | 0.190 |
Why?
|
| Hyperlipidemias | 4 | 2001 | 771 | 0.190 |
Why?
|
| Mental Disorders | 3 | 2017 | 6803 | 0.190 |
Why?
|
| Carotid Artery Diseases | 1 | 2007 | 872 | 0.190 |
Why?
|
| Societies, Medical | 6 | 2019 | 3891 | 0.180 |
Why?
|
| Body Surface Area | 3 | 2013 | 197 | 0.180 |
Why?
|
| Mycobacterium Infections | 1 | 2021 | 121 | 0.180 |
Why?
|
| Cerebrovascular Disorders | 3 | 2006 | 1475 | 0.180 |
Why?
|
| Aorta | 5 | 2023 | 2037 | 0.180 |
Why?
|
| Treatment Failure | 5 | 2023 | 2640 | 0.180 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 3 | 2021 | 321 | 0.180 |
Why?
|
| Memory Disorders | 2 | 2018 | 1198 | 0.180 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 4 | 2024 | 2782 | 0.180 |
Why?
|
| Seizures | 5 | 2018 | 2919 | 0.180 |
Why?
|
| Hemosiderin | 2 | 2010 | 41 | 0.170 |
Why?
|
| Sex Factors | 8 | 2017 | 10505 | 0.170 |
Why?
|
| Arteries | 3 | 2022 | 1125 | 0.170 |
Why?
|
| Reproducibility of Results | 16 | 2023 | 20052 | 0.170 |
Why?
|
| California | 4 | 2019 | 1419 | 0.170 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2022 | 273 | 0.170 |
Why?
|
| Antithrombin III | 1 | 2020 | 128 | 0.170 |
Why?
|
| Severity of Illness Index | 15 | 2024 | 15785 | 0.170 |
Why?
|
| Program Evaluation | 3 | 2018 | 2490 | 0.170 |
Why?
|
| Disease Progression | 9 | 2023 | 13468 | 0.170 |
Why?
|
| Enteritis | 1 | 2021 | 162 | 0.170 |
Why?
|
| Bacterial Infections | 4 | 2021 | 1401 | 0.170 |
Why?
|
| Morbidity | 4 | 2023 | 1754 | 0.170 |
Why?
|
| Birth Weight | 2 | 2019 | 2097 | 0.170 |
Why?
|
| Cerebral Cortex | 5 | 2024 | 5759 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 11 | 2016 | 7377 | 0.170 |
Why?
|
| Interferon Type I | 1 | 2023 | 559 | 0.170 |
Why?
|
| Intercellular Adhesion Molecule-1 | 5 | 2003 | 1125 | 0.170 |
Why?
|
| Anti-Ulcer Agents | 1 | 2020 | 112 | 0.170 |
Why?
|
| Cause of Death | 5 | 2019 | 3674 | 0.170 |
Why?
|
| Human Growth Hormone | 1 | 2004 | 638 | 0.170 |
Why?
|
| History, 20th Century | 3 | 2016 | 2772 | 0.160 |
Why?
|
| Ambulatory Care | 4 | 2020 | 2768 | 0.160 |
Why?
|
| Regression Analysis | 6 | 2021 | 6353 | 0.160 |
Why?
|
| Multivariate Analysis | 11 | 2019 | 12096 | 0.160 |
Why?
|
| Multicenter Studies as Topic | 6 | 2023 | 1705 | 0.160 |
Why?
|
| Histamine H2 Antagonists | 1 | 2020 | 165 | 0.160 |
Why?
|
| Fetal Therapies | 1 | 2020 | 101 | 0.160 |
Why?
|
| Double-Blind Method | 10 | 2020 | 12262 | 0.160 |
Why?
|
| Ventricular Remodeling | 2 | 2019 | 1256 | 0.160 |
Why?
|
| Atrioventricular Block | 1 | 2020 | 120 | 0.160 |
Why?
|
| Stroke Volume | 8 | 2023 | 5460 | 0.160 |
Why?
|
| Cerebrum | 1 | 2020 | 132 | 0.160 |
Why?
|
| Pyrazoles | 2 | 2019 | 1990 | 0.160 |
Why?
|
| Dental Care for Chronically Ill | 3 | 2008 | 32 | 0.160 |
Why?
|
| Intelligence | 2 | 2004 | 921 | 0.160 |
Why?
|
| Space Perception | 3 | 2014 | 464 | 0.160 |
Why?
|
| Thoracic Duct | 1 | 2018 | 64 | 0.160 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2004 | 818 | 0.160 |
Why?
|
| Myosin Heavy Chains | 2 | 2017 | 402 | 0.150 |
Why?
|
| Constriction, Pathologic | 2 | 2022 | 1097 | 0.150 |
Why?
|
| Pregnancy | 11 | 2024 | 29742 | 0.150 |
Why?
|
| Decision Trees | 1 | 2020 | 504 | 0.150 |
Why?
|
| Cost Savings | 3 | 2020 | 918 | 0.150 |
Why?
|
| Cardiovascular Diseases | 9 | 2020 | 15396 | 0.150 |
Why?
|
| Growth Differentiation Factor 1 | 1 | 2017 | 6 | 0.150 |
Why?
|
| Mannose-Binding Lectin | 1 | 2019 | 146 | 0.150 |
Why?
|
| Occupations | 1 | 2020 | 515 | 0.150 |
Why?
|
| Quality Improvement | 6 | 2020 | 3806 | 0.150 |
Why?
|
| Sex Distribution | 3 | 2014 | 2283 | 0.150 |
Why?
|
| Chylothorax | 1 | 2018 | 83 | 0.150 |
Why?
|
| Lymphography | 1 | 2018 | 188 | 0.150 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2022 | 578 | 0.150 |
Why?
|
| Chemoprevention | 1 | 2020 | 326 | 0.150 |
Why?
|
| Managed Care Programs | 2 | 2000 | 939 | 0.150 |
Why?
|
| Myocardium | 10 | 2022 | 4690 | 0.150 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2019 | 326 | 0.150 |
Why?
|
| Dextrocardia | 1 | 2017 | 37 | 0.150 |
Why?
|
| Selectins | 1 | 1997 | 101 | 0.150 |
Why?
|
| Cerebral Hemorrhage | 1 | 2009 | 2650 | 0.150 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2017 | 51 | 0.150 |
Why?
|
| Adenosine Deaminase | 1 | 2019 | 251 | 0.140 |
Why?
|
| Quality Assurance, Health Care | 3 | 2020 | 2167 | 0.140 |
Why?
|
| New York | 4 | 2024 | 874 | 0.140 |
Why?
|
| Survival Rate | 9 | 2021 | 12721 | 0.140 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2017 | 69 | 0.140 |
Why?
|
| Antithrombins | 1 | 2020 | 294 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2017 | 119 | 0.140 |
Why?
|
| Congresses as Topic | 2 | 2019 | 799 | 0.140 |
Why?
|
| Cardiac Myosins | 1 | 2017 | 127 | 0.140 |
Why?
|
| Acid-Base Equilibrium | 1 | 1997 | 180 | 0.140 |
Why?
|
| Depression | 1 | 2017 | 8057 | 0.140 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2020 | 1431 | 0.140 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2024 | 1110 | 0.140 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2019 | 285 | 0.140 |
Why?
|
| Genes, Recessive | 1 | 2019 | 626 | 0.140 |
Why?
|
| Genes, Dominant | 1 | 2019 | 862 | 0.140 |
Why?
|
| Health Resources | 2 | 2015 | 931 | 0.140 |
Why?
|
| Pacemaker, Artificial | 2 | 2015 | 808 | 0.140 |
Why?
|
| Fibrinogen | 1 | 2020 | 883 | 0.140 |
Why?
|
| DNA, Mitochondrial | 1 | 2022 | 856 | 0.140 |
Why?
|
| RNA, Untranslated | 1 | 2020 | 459 | 0.140 |
Why?
|
| Hypolipidemic Agents | 3 | 2018 | 609 | 0.130 |
Why?
|
| Socioeconomic Factors | 5 | 2022 | 7817 | 0.130 |
Why?
|
| Cholesterol, HDL | 4 | 2006 | 1808 | 0.130 |
Why?
|
| Troponin | 3 | 2023 | 500 | 0.130 |
Why?
|
| Prevalence | 14 | 2020 | 15646 | 0.130 |
Why?
|
| Losartan | 1 | 2018 | 265 | 0.130 |
Why?
|
| Motor Skills | 1 | 1999 | 519 | 0.130 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2017 | 213 | 0.130 |
Why?
|
| Research | 2 | 2015 | 1976 | 0.130 |
Why?
|
| Ultrasonography | 6 | 2014 | 5952 | 0.130 |
Why?
|
| CpG Islands | 1 | 2020 | 1221 | 0.130 |
Why?
|
| Blood Pressure | 8 | 2021 | 8453 | 0.130 |
Why?
|
| Ethinyl Estradiol | 3 | 1988 | 114 | 0.130 |
Why?
|
| Japan | 2 | 2018 | 1366 | 0.130 |
Why?
|
| Research Design | 7 | 2024 | 6154 | 0.130 |
Why?
|
| Remission, Spontaneous | 1 | 2016 | 384 | 0.130 |
Why?
|
| Survival Analysis | 8 | 2016 | 10112 | 0.130 |
Why?
|
| Heart Arrest | 2 | 2023 | 1494 | 0.130 |
Why?
|
| Psychopathology | 1 | 2018 | 429 | 0.130 |
Why?
|
| Reference Values | 7 | 2019 | 4919 | 0.130 |
Why?
|
| Visual Perception | 2 | 2003 | 1374 | 0.130 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 6821 | 0.130 |
Why?
|
| Matrix Metalloproteinases | 2 | 2010 | 392 | 0.130 |
Why?
|
| Cattle | 2 | 2019 | 3846 | 0.130 |
Why?
|
| Vision, Ocular | 1 | 2018 | 454 | 0.130 |
Why?
|
| Language Development | 1 | 2016 | 181 | 0.130 |
Why?
|
| Blood Coagulation | 1 | 2021 | 1149 | 0.130 |
Why?
|
| International Normalized Ratio | 1 | 2017 | 382 | 0.120 |
Why?
|
| Drug Administration Schedule | 6 | 2017 | 4839 | 0.120 |
Why?
|
| Mental Health | 2 | 2020 | 3232 | 0.120 |
Why?
|
| Patient Selection | 5 | 2018 | 4244 | 0.120 |
Why?
|
| Cyclophosphamide | 1 | 2021 | 2218 | 0.120 |
Why?
|
| Sensitivity and Specificity | 11 | 2020 | 14641 | 0.120 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 1997 | 691 | 0.120 |
Why?
|
| Fetal Development | 1 | 2020 | 766 | 0.120 |
Why?
|
| Endpoint Determination | 1 | 2018 | 590 | 0.120 |
Why?
|
| Aortic Diseases | 1 | 2001 | 735 | 0.120 |
Why?
|
| Defibrillators | 1 | 2015 | 39 | 0.120 |
Why?
|
| Clinical Protocols | 2 | 2020 | 1436 | 0.120 |
Why?
|
| Respiratory Insufficiency | 1 | 2023 | 1230 | 0.120 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 933 | 0.120 |
Why?
|
| Hospitals, University | 1 | 2016 | 567 | 0.120 |
Why?
|
| Efficiency, Organizational | 1 | 2019 | 696 | 0.120 |
Why?
|
| Cerebral Angiography | 1 | 2020 | 1275 | 0.120 |
Why?
|
| Parent-Child Relations | 1 | 2019 | 759 | 0.120 |
Why?
|
| Chorea | 2 | 2007 | 79 | 0.120 |
Why?
|
| Cluster Analysis | 1 | 2021 | 2697 | 0.120 |
Why?
|
| Program Development | 5 | 2011 | 1297 | 0.120 |
Why?
|
| Cardiovascular Agents | 2 | 2018 | 839 | 0.120 |
Why?
|
| Heart Block | 1 | 2016 | 392 | 0.120 |
Why?
|
| Infant, Premature | 2 | 2023 | 2092 | 0.120 |
Why?
|
| Patient Compliance | 2 | 2023 | 2685 | 0.120 |
Why?
|
| Diffusion of Innovation | 2 | 2016 | 728 | 0.120 |
Why?
|
| Cerebral Ventricles | 1 | 2017 | 542 | 0.120 |
Why?
|
| Lymphoma | 1 | 2023 | 1896 | 0.120 |
Why?
|
| Congenital Abnormalities | 3 | 2015 | 704 | 0.120 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2020 | 1156 | 0.120 |
Why?
|
| Steroids | 3 | 2020 | 926 | 0.110 |
Why?
|
| Pilot Projects | 5 | 2024 | 8554 | 0.110 |
Why?
|
| Milrinone | 1 | 2014 | 86 | 0.110 |
Why?
|
| Patient Care | 1 | 2019 | 622 | 0.110 |
Why?
|
| Radiographic Image Enhancement | 1 | 2018 | 875 | 0.110 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2014 | 54 | 0.110 |
Why?
|
| Cephalometry | 1 | 2015 | 382 | 0.110 |
Why?
|
| Mathematics | 7 | 2021 | 707 | 0.110 |
Why?
|
| Bacteremia | 6 | 2008 | 980 | 0.110 |
Why?
|
| Lipids | 2 | 1997 | 3326 | 0.110 |
Why?
|
| Genetic Diseases, Inborn | 2 | 2015 | 601 | 0.110 |
Why?
|
| Hemorrhage | 4 | 2020 | 3400 | 0.110 |
Why?
|
| Renin-Angiotensin System | 1 | 2018 | 733 | 0.110 |
Why?
|
| Attitude of Health Personnel | 3 | 2011 | 3867 | 0.110 |
Why?
|
| Body Mass Index | 6 | 2022 | 12876 | 0.110 |
Why?
|
| Coronary Occlusion | 1 | 2016 | 303 | 0.110 |
Why?
|
| Enalapril | 2 | 2015 | 311 | 0.110 |
Why?
|
| Hyperlipoproteinemias | 1 | 1993 | 20 | 0.110 |
Why?
|
| Health Surveys | 3 | 2021 | 4060 | 0.110 |
Why?
|
| Likelihood Functions | 1 | 2016 | 987 | 0.110 |
Why?
|
| Longitudinal Studies | 6 | 2021 | 14481 | 0.110 |
Why?
|
| RNA | 1 | 2023 | 2716 | 0.110 |
Why?
|
| Contrast Media | 3 | 2022 | 5298 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 4 | 2020 | 5484 | 0.110 |
Why?
|
| Heart Bypass, Right | 2 | 2010 | 75 | 0.110 |
Why?
|
| Communicable Diseases | 1 | 2021 | 877 | 0.110 |
Why?
|
| Memory | 2 | 2014 | 2179 | 0.110 |
Why?
|
| Diastole | 3 | 2014 | 781 | 0.110 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2011 | 932 | 0.110 |
Why?
|
| Chromatin | 2 | 2023 | 2938 | 0.100 |
Why?
|
| Standard of Care | 2 | 2019 | 550 | 0.100 |
Why?
|
| Virus Diseases | 2 | 2021 | 719 | 0.100 |
Why?
|
| Hospitals | 3 | 2021 | 3888 | 0.100 |
Why?
|
| Heparin | 1 | 2020 | 1632 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2020 | 15773 | 0.100 |
Why?
|
| Hyperlipoproteinemia Type II | 3 | 2015 | 393 | 0.100 |
Why?
|
| Immunoglobulin G | 4 | 2020 | 4540 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 5 | 1980 | 1090 | 0.100 |
Why?
|
| Access to Information | 1 | 2015 | 318 | 0.100 |
Why?
|
| Niacin | 1 | 1993 | 118 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 1651 | 0.100 |
Why?
|
| Affect | 1 | 2020 | 1480 | 0.100 |
Why?
|
| Guideline Adherence | 2 | 2021 | 2215 | 0.100 |
Why?
|
| Myocardial Revascularization | 1 | 2016 | 792 | 0.100 |
Why?
|
| Attention | 2 | 2014 | 2387 | 0.100 |
Why?
|
| Watchful Waiting | 1 | 2016 | 509 | 0.100 |
Why?
|
| Wechsler Scales | 2 | 2003 | 257 | 0.100 |
Why?
|
| Genetic Variation | 3 | 2021 | 6548 | 0.100 |
Why?
|
| Prosthesis Design | 1 | 2019 | 2105 | 0.100 |
Why?
|
| Prosthesis-Related Infections | 2 | 2010 | 486 | 0.100 |
Why?
|
| Apolipoprotein E4 | 1 | 2016 | 706 | 0.100 |
Why?
|
| Anxiety | 3 | 2023 | 4538 | 0.100 |
Why?
|
| Age of Onset | 5 | 2021 | 3298 | 0.100 |
Why?
|
| Child Behavior | 4 | 2020 | 847 | 0.100 |
Why?
|
| Tobacco Smoke Pollution | 1 | 1997 | 812 | 0.100 |
Why?
|
| Consensus Development Conferences as Topic | 2 | 2011 | 168 | 0.100 |
Why?
|
| Mass Screening | 4 | 2012 | 5425 | 0.100 |
Why?
|
| Hypoxia, Brain | 1 | 2012 | 138 | 0.090 |
Why?
|
| Linkage Disequilibrium | 5 | 2011 | 1996 | 0.090 |
Why?
|
| Uric Acid | 4 | 1979 | 803 | 0.090 |
Why?
|
| Behavior | 1 | 2014 | 540 | 0.090 |
Why?
|
| Antibodies, Viral | 2 | 2020 | 3142 | 0.090 |
Why?
|
| Systole | 3 | 2015 | 936 | 0.090 |
Why?
|
| Thalamus | 1 | 2017 | 1040 | 0.090 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1993 | 362 | 0.090 |
Why?
|
| Organ Size | 4 | 2018 | 2252 | 0.090 |
Why?
|
| Running | 2 | 2006 | 483 | 0.090 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2011 | 1401 | 0.090 |
Why?
|
| Connecticut | 1 | 2011 | 365 | 0.090 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 726 | 0.090 |
Why?
|
| Critical Care | 4 | 2020 | 2692 | 0.090 |
Why?
|
| Intensive Care Units | 3 | 2020 | 3732 | 0.090 |
Why?
|
| Hepatomegaly | 1 | 2010 | 84 | 0.090 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 69 | 0.090 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2011 | 105 | 0.090 |
Why?
|
| Professional Misconduct | 1 | 2011 | 73 | 0.090 |
Why?
|
| Advisory Committees | 1 | 2015 | 785 | 0.090 |
Why?
|
| Regional Blood Flow | 1 | 2014 | 1486 | 0.090 |
Why?
|
| Health Planning Guidelines | 2 | 2008 | 151 | 0.090 |
Why?
|
| GPI-Linked Proteins | 1 | 2012 | 468 | 0.090 |
Why?
|
| New Zealand | 2 | 2021 | 352 | 0.090 |
Why?
|
| Data Mining | 1 | 2015 | 551 | 0.090 |
Why?
|
| Growth Disorders | 1 | 2015 | 653 | 0.090 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2020 | 1162 | 0.090 |
Why?
|
| Intracranial Aneurysm | 1 | 2020 | 1276 | 0.090 |
Why?
|
| Hyperglycemia | 2 | 2013 | 1368 | 0.090 |
Why?
|
| Caregivers | 1 | 2022 | 2224 | 0.090 |
Why?
|
| Comorbidity | 7 | 2023 | 10495 | 0.090 |
Why?
|
| Interviews as Topic | 1 | 2018 | 2675 | 0.090 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2020 | 1704 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2016 | 1240 | 0.090 |
Why?
|
| Carotid Arteries | 1 | 2014 | 939 | 0.090 |
Why?
|
| Cross-Over Studies | 3 | 2019 | 2048 | 0.090 |
Why?
|
| Software | 2 | 2024 | 4416 | 0.090 |
Why?
|
| Forecasting | 2 | 2016 | 2920 | 0.090 |
Why?
|
| Antirheumatic Agents | 2 | 2019 | 1368 | 0.090 |
Why?
|
| Collateral Circulation | 1 | 2011 | 292 | 0.090 |
Why?
|
| Social Perception | 1 | 2014 | 432 | 0.090 |
Why?
|
| Endothelium, Vascular | 5 | 2009 | 4429 | 0.090 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 2001 | 2497 | 0.090 |
Why?
|
| Inflammation | 7 | 2023 | 10719 | 0.090 |
Why?
|
| Massachusetts | 3 | 2021 | 8823 | 0.080 |
Why?
|
| Statistics, Nonparametric | 3 | 2011 | 2850 | 0.080 |
Why?
|
| Phlebography | 1 | 2011 | 325 | 0.080 |
Why?
|
| Genome, Human | 2 | 2020 | 4415 | 0.080 |
Why?
|
| Reaction Time | 1 | 2016 | 2075 | 0.080 |
Why?
|
| Genome-Wide Association Study | 5 | 2019 | 12604 | 0.080 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 1292 | 0.080 |
Why?
|
| Gene Frequency | 4 | 2023 | 3612 | 0.080 |
Why?
|
| Hypertension | 7 | 2021 | 8503 | 0.080 |
Why?
|
| Neurogenesis | 1 | 2015 | 855 | 0.080 |
Why?
|
| Hospital Costs | 2 | 2018 | 960 | 0.080 |
Why?
|
| Guidelines as Topic | 2 | 2016 | 1386 | 0.080 |
Why?
|
| Quality of Health Care | 3 | 2012 | 4317 | 0.080 |
Why?
|
| Retreatment | 1 | 2010 | 596 | 0.080 |
Why?
|
| Pulse | 1 | 2009 | 218 | 0.080 |
Why?
|
| Oxonic Acid | 2 | 1979 | 31 | 0.080 |
Why?
|
| Motor Activity | 2 | 2016 | 2686 | 0.080 |
Why?
|
| Image Enhancement | 2 | 2016 | 2880 | 0.080 |
Why?
|
| Psychometrics | 4 | 2024 | 3050 | 0.080 |
Why?
|
| Atherosclerosis | 5 | 2014 | 3401 | 0.080 |
Why?
|
| Hypercholesterolemia | 2 | 2007 | 1139 | 0.080 |
Why?
|
| Periodontal Diseases | 1 | 2012 | 451 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2018 | 8946 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2015 | 1503 | 0.080 |
Why?
|
| Inpatients | 2 | 2023 | 2551 | 0.080 |
Why?
|
| Confidence Intervals | 3 | 2008 | 2925 | 0.080 |
Why?
|
| Genetic Loci | 2 | 2012 | 2612 | 0.080 |
Why?
|
| Odds Ratio | 8 | 2020 | 9650 | 0.080 |
Why?
|
| Platelet Function Tests | 1 | 2010 | 271 | 0.080 |
Why?
|
| Neonatal Screening | 2 | 2009 | 594 | 0.080 |
Why?
|
| Sports | 2 | 2023 | 699 | 0.080 |
Why?
|
| Sample Size | 3 | 2019 | 838 | 0.070 |
Why?
|
| RNA Splicing | 3 | 2023 | 913 | 0.070 |
Why?
|
| Risk | 6 | 2017 | 9599 | 0.070 |
Why?
|
| Caspase 3 | 1 | 2010 | 728 | 0.070 |
Why?
|
| Genetic Markers | 2 | 2012 | 2608 | 0.070 |
Why?
|
| Coronary Circulation | 1 | 2014 | 1561 | 0.070 |
Why?
|
| Leukomalacia, Periventricular | 1 | 2009 | 184 | 0.070 |
Why?
|
| Arteriovenous Malformations | 1 | 2011 | 397 | 0.070 |
Why?
|
| Attitude to Health | 2 | 2009 | 2025 | 0.070 |
Why?
|
| Tachycardia, Ventricular | 1 | 2016 | 1297 | 0.070 |
Why?
|
| Medication Therapy Management | 1 | 2008 | 130 | 0.070 |
Why?
|
| Pulse Therapy, Drug | 1 | 2007 | 36 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 3754 | 0.070 |
Why?
|
| Risk Adjustment | 2 | 2020 | 600 | 0.070 |
Why?
|
| Information Dissemination | 1 | 2015 | 1128 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2024 | 4761 | 0.070 |
Why?
|
| Health Care Costs | 1 | 2020 | 3245 | 0.070 |
Why?
|
| Inflammation Mediators | 2 | 2019 | 1878 | 0.070 |
Why?
|
| Truth Disclosure | 1 | 2011 | 432 | 0.070 |
Why?
|
| Central Nervous System Diseases | 2 | 2009 | 520 | 0.070 |
Why?
|
| Markov Chains | 2 | 2020 | 965 | 0.070 |
Why?
|
| Exercise | 1 | 2023 | 5788 | 0.070 |
Why?
|
| Diabetes Mellitus | 3 | 2022 | 5818 | 0.070 |
Why?
|
| Triazines | 2 | 1979 | 310 | 0.070 |
Why?
|
| Heart Septal Defects, Atrial | 3 | 2005 | 460 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2020 | 4373 | 0.070 |
Why?
|
| Alleles | 3 | 2011 | 6895 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2020 | 3339 | 0.070 |
Why?
|
| Riboflavin | 2 | 1977 | 105 | 0.070 |
Why?
|
| Electroencephalography | 6 | 2004 | 6187 | 0.070 |
Why?
|
| Patient Readmission | 2 | 2014 | 3261 | 0.070 |
Why?
|
| Mutation | 6 | 2023 | 29915 | 0.070 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 3362 | 0.070 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2022 | 3758 | 0.070 |
Why?
|
| Blood Sedimentation | 2 | 2019 | 234 | 0.070 |
Why?
|
| Cholesterol, LDL | 4 | 1998 | 2374 | 0.070 |
Why?
|
| Data Collection | 3 | 2016 | 3322 | 0.060 |
Why?
|
| Haplotypes | 4 | 2011 | 2764 | 0.060 |
Why?
|
| Lactic Acid | 4 | 2012 | 1133 | 0.060 |
Why?
|
| Drug Prescriptions | 1 | 2015 | 1668 | 0.060 |
Why?
|
| Databases as Topic | 1 | 2007 | 472 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 3446 | 0.060 |
Why?
|
| Early Diagnosis | 3 | 2020 | 1177 | 0.060 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 2108 | 0.060 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2007 | 435 | 0.060 |
Why?
|
| Calcinosis | 1 | 2014 | 1467 | 0.060 |
Why?
|
| Heart Valves | 2 | 2024 | 284 | 0.060 |
Why?
|
| Brachial Artery | 2 | 2009 | 365 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2011 | 1573 | 0.060 |
Why?
|
| Cardiovascular System | 1 | 2012 | 835 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 19 | 2 | 2011 | 347 | 0.060 |
Why?
|
| Kidney Diseases | 3 | 2007 | 2083 | 0.060 |
Why?
|
| Dyslipidemias | 2 | 2015 | 868 | 0.060 |
Why?
|
| Counseling | 1 | 1993 | 1541 | 0.060 |
Why?
|
| Triiodobenzoic Acids | 1 | 2005 | 123 | 0.060 |
Why?
|
| Cerebral Infarction | 1 | 2010 | 981 | 0.060 |
Why?
|
| Pulmonary Veins | 1 | 2011 | 745 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2024 | 12096 | 0.060 |
Why?
|
| Social Behavior | 1 | 2011 | 1132 | 0.060 |
Why?
|
| Cardiomyopathies | 2 | 2015 | 1944 | 0.060 |
Why?
|
| Particulate Matter | 1 | 2016 | 2556 | 0.060 |
Why?
|
| Neutrophil Activation | 1 | 2005 | 181 | 0.060 |
Why?
|
| Career Choice | 1 | 2011 | 752 | 0.060 |
Why?
|
| Amlodipine | 1 | 2004 | 84 | 0.060 |
Why?
|
| Animals | 17 | 2024 | 167777 | 0.060 |
Why?
|
| Family | 3 | 2005 | 3188 | 0.060 |
Why?
|
| Analysis of Variance | 6 | 2014 | 6233 | 0.060 |
Why?
|
| Chemokines, CC | 1 | 2005 | 283 | 0.060 |
Why?
|
| Facial Paralysis | 1 | 2008 | 345 | 0.060 |
Why?
|
| Pedigree | 2 | 2017 | 4578 | 0.060 |
Why?
|
| Hungary | 1 | 2004 | 82 | 0.060 |
Why?
|
| Insurance Claim Review | 2 | 2021 | 737 | 0.060 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2011 | 695 | 0.060 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2024 | 1088 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2005 | 385 | 0.060 |
Why?
|
| Postoperative Hemorrhage | 1 | 2007 | 413 | 0.060 |
Why?
|
| Multigene Family | 2 | 2011 | 1076 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2016 | 3046 | 0.060 |
Why?
|
| Risk Reduction Behavior | 2 | 2007 | 1098 | 0.060 |
Why?
|
| Triiodothyronine | 1 | 2005 | 493 | 0.060 |
Why?
|
| Disease Management | 2 | 2012 | 2500 | 0.060 |
Why?
|
| Platelet Count | 2 | 2021 | 775 | 0.050 |
Why?
|
| Health Policy | 3 | 2013 | 2675 | 0.050 |
Why?
|
| Endocarditis | 3 | 2010 | 349 | 0.050 |
Why?
|
| Social Adjustment | 2 | 2003 | 632 | 0.050 |
Why?
|
| RNA, Messenger | 6 | 2015 | 12760 | 0.050 |
Why?
|
| Eisenmenger Complex | 1 | 2003 | 26 | 0.050 |
Why?
|
| RNA-Directed DNA Polymerase | 3 | 1990 | 224 | 0.050 |
Why?
|
| Heart Auscultation | 1 | 1983 | 34 | 0.050 |
Why?
|
| Hydrocortisone | 1 | 2011 | 1802 | 0.050 |
Why?
|
| Epistaxis | 1 | 2023 | 111 | 0.050 |
Why?
|
| HLA-DR Antigens | 2 | 2023 | 630 | 0.050 |
Why?
|
| Receptors, CCR5 | 1 | 2005 | 487 | 0.050 |
Why?
|
| Consensus | 3 | 2018 | 3099 | 0.050 |
Why?
|
| Canada | 2 | 2020 | 2111 | 0.050 |
Why?
|
| Australia | 2 | 2020 | 1235 | 0.050 |
Why?
|
| Interleukin-15 | 1 | 2023 | 183 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 1957 | 0.050 |
Why?
|
| Cyclosporins | 1 | 1983 | 216 | 0.050 |
Why?
|
| Athetosis | 1 | 2002 | 15 | 0.050 |
Why?
|
| Heart Murmurs | 1 | 1983 | 93 | 0.050 |
Why?
|
| Weight Lifting | 1 | 2023 | 126 | 0.050 |
Why?
|
| Histones | 1 | 2013 | 2577 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2004 | 415 | 0.050 |
Why?
|
| Diagnostic Imaging | 2 | 2016 | 3526 | 0.050 |
Why?
|
| Elasticity | 2 | 2015 | 652 | 0.050 |
Why?
|
| Anisotropy | 2 | 2017 | 1278 | 0.050 |
Why?
|
| Ulcer | 1 | 2024 | 204 | 0.050 |
Why?
|
| Hyponatremia | 1 | 2005 | 279 | 0.050 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2004 | 590 | 0.050 |
Why?
|
| Depressive Disorder, Major | 1 | 2020 | 4745 | 0.050 |
Why?
|
| Autonomic Nervous System | 1 | 2007 | 697 | 0.050 |
Why?
|
| Phenotype | 5 | 2020 | 16534 | 0.050 |
Why?
|
| Lymphadenitis | 2 | 2021 | 98 | 0.050 |
Why?
|
| Epoprostenol | 1 | 2003 | 246 | 0.050 |
Why?
|
| Athletic Injuries | 1 | 2012 | 1211 | 0.050 |
Why?
|
| Oscillometry | 1 | 1982 | 145 | 0.050 |
Why?
|
| Nitroglycerin | 1 | 2023 | 328 | 0.050 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2005 | 352 | 0.050 |
Why?
|
| Obesity | 6 | 2022 | 12870 | 0.050 |
Why?
|
| Mycobacterium avium Complex | 1 | 2021 | 59 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2005 | 1130 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 3 | 2014 | 281 | 0.050 |
Why?
|
| Genes, Immediate-Early | 1 | 2002 | 102 | 0.050 |
Why?
|
| Acute Coronary Syndrome | 1 | 2014 | 2180 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2016 | 4411 | 0.050 |
Why?
|
| Anastomosis, Surgical | 3 | 2013 | 983 | 0.050 |
Why?
|
| Seasons | 1 | 2007 | 1519 | 0.050 |
Why?
|
| American Dental Association | 3 | 2008 | 16 | 0.050 |
Why?
|
| Blood Circulation | 1 | 1982 | 249 | 0.050 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 7810 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2004 | 694 | 0.050 |
Why?
|
| Insurance, Health | 2 | 2018 | 2495 | 0.050 |
Why?
|
| Catheter Ablation | 2 | 2024 | 2740 | 0.050 |
Why?
|
| Comparative Effectiveness Research | 2 | 2019 | 715 | 0.050 |
Why?
|
| Interleukin-10 | 2 | 2020 | 1174 | 0.050 |
Why?
|
| Educational Measurement | 2 | 2015 | 1248 | 0.050 |
Why?
|
| Exercise Test | 3 | 2014 | 2121 | 0.050 |
Why?
|
| Human Experimentation | 1 | 2001 | 123 | 0.050 |
Why?
|
| Blood Flow Velocity | 2 | 2007 | 1370 | 0.050 |
Why?
|
| Child Welfare | 2 | 2001 | 516 | 0.040 |
Why?
|
| Intention to Treat Analysis | 2 | 2013 | 414 | 0.040 |
Why?
|
| Stroke | 2 | 2015 | 9696 | 0.040 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2009 | 1745 | 0.040 |
Why?
|
| Weight Gain | 2 | 2014 | 2346 | 0.040 |
Why?
|
| Myocardial Reperfusion Injury | 2 | 2002 | 478 | 0.040 |
Why?
|
| Polymorphism, Genetic | 3 | 2007 | 4284 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2013 | 6347 | 0.040 |
Why?
|
| Cardiotonic Agents | 2 | 2014 | 539 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2009 | 2414 | 0.040 |
Why?
|
| Interleukin-8 | 2 | 2010 | 696 | 0.040 |
Why?
|
| Equipment Contamination | 1 | 2021 | 179 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2008 | 1660 | 0.040 |
Why?
|
| Defibrillators, Implantable | 1 | 2010 | 1487 | 0.040 |
Why?
|
| Conjunctivitis | 1 | 2021 | 155 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 3069 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2020 | 1722 | 0.040 |
Why?
|
| Random Allocation | 4 | 1989 | 2385 | 0.040 |
Why?
|
| Chromosome Disorders | 1 | 2003 | 499 | 0.040 |
Why?
|
| Mycobacterium | 1 | 2021 | 250 | 0.040 |
Why?
|
| Receptor, Notch1 | 1 | 2023 | 495 | 0.040 |
Why?
|
| Discriminant Analysis | 1 | 2020 | 222 | 0.040 |
Why?
|
| Abdominal Pain | 2 | 2021 | 1063 | 0.040 |
Why?
|
| Kinetics | 8 | 1986 | 6371 | 0.040 |
Why?
|
| Time | 1 | 2001 | 543 | 0.040 |
Why?
|
| Chemokine CXCL9 | 1 | 2019 | 135 | 0.040 |
Why?
|
| Italy | 1 | 2021 | 839 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2021 | 565 | 0.040 |
Why?
|
| Quaternary Ammonium Compounds | 2 | 1977 | 202 | 0.040 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2021 | 1014 | 0.040 |
Why?
|
| ROC Curve | 2 | 2022 | 3563 | 0.040 |
Why?
|
| Middle Aged | 17 | 2021 | 219560 | 0.040 |
Why?
|
| Chi-Square Distribution | 3 | 2014 | 3425 | 0.040 |
Why?
|
| Observer Variation | 2 | 2016 | 2600 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 617 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2011 | 635 | 0.040 |
Why?
|
| Thrombelastography | 1 | 2021 | 183 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2020 | 315 | 0.040 |
Why?
|
| Antibodies | 2 | 2023 | 2420 | 0.040 |
Why?
|
| Internship and Residency | 2 | 2015 | 5865 | 0.040 |
Why?
|
| Water | 2 | 2005 | 1402 | 0.040 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2021 | 267 | 0.040 |
Why?
|
| Genes, Neoplasm | 1 | 2021 | 370 | 0.040 |
Why?
|
| RNA-Binding Proteins | 2 | 2020 | 1895 | 0.040 |
Why?
|
| Monitoring, Physiologic | 3 | 2013 | 1780 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 778 | 0.040 |
Why?
|
| Body Height | 2 | 2016 | 1567 | 0.040 |
Why?
|
| Learning Curve | 1 | 2021 | 231 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2020 | 362 | 0.040 |
Why?
|
| Repressor Proteins | 2 | 2023 | 2980 | 0.040 |
Why?
|
| Shock | 1 | 2021 | 314 | 0.040 |
Why?
|
| Injections, Intravenous | 5 | 1992 | 1378 | 0.040 |
Why?
|
| Peer Review, Health Care | 1 | 2019 | 73 | 0.040 |
Why?
|
| Mouth Mucosa | 1 | 2021 | 426 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 418 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2011 | 940 | 0.040 |
Why?
|
| Perioperative Care | 2 | 2019 | 1028 | 0.040 |
Why?
|
| Mammals | 1 | 2024 | 1132 | 0.040 |
Why?
|
| Thrombolytic Therapy | 2 | 2013 | 2060 | 0.040 |
Why?
|
| Relative Value Scales | 1 | 1998 | 86 | 0.040 |
Why?
|
| Efficiency | 1 | 2021 | 477 | 0.040 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2020 | 264 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 1982 | 634 | 0.040 |
Why?
|
| Insulin | 1 | 2013 | 6578 | 0.040 |
Why?
|
| Trichloroacetic Acid | 2 | 1977 | 48 | 0.040 |
Why?
|
| Genotype | 4 | 2019 | 12945 | 0.040 |
Why?
|
| Heart-Assist Devices | 2 | 2010 | 1279 | 0.040 |
Why?
|
| Head | 1 | 2004 | 921 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2019 | 250 | 0.040 |
Why?
|
| Kidney | 2 | 1991 | 7016 | 0.040 |
Why?
|
| Quality Control | 2 | 2017 | 825 | 0.040 |
Why?
|
| Vaccination | 2 | 2023 | 3356 | 0.040 |
Why?
|
| Pulmonary Valve Stenosis | 2 | 2005 | 172 | 0.040 |
Why?
|
| Health Personnel | 1 | 2011 | 3311 | 0.040 |
Why?
|
| Cross Infection | 2 | 2020 | 1432 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2023 | 3175 | 0.040 |
Why?
|
| Occipital Lobe | 1 | 2019 | 373 | 0.040 |
Why?
|
| Interleukin-17 | 1 | 2023 | 908 | 0.040 |
Why?
|
| Binding Sites | 2 | 2020 | 6036 | 0.040 |
Why?
|
| Fibrosis | 2 | 2015 | 2038 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 20500 | 0.040 |
Why?
|
| Bacteriophages | 1 | 2020 | 372 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2021 | 1593 | 0.040 |
Why?
|
| Tachycardia | 1 | 1979 | 600 | 0.040 |
Why?
|
| Intraoperative Complications | 1 | 2004 | 1184 | 0.040 |
Why?
|
| Hypertension, Pulmonary | 2 | 2004 | 1565 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 2001 | 1055 | 0.040 |
Why?
|
| Gadolinium | 1 | 2022 | 959 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2020 | 814 | 0.030 |
Why?
|
| Vitamin K | 1 | 2019 | 318 | 0.030 |
Why?
|
| Mosaicism | 1 | 2020 | 465 | 0.030 |
Why?
|
| Missouri | 1 | 2016 | 114 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 3990 | 0.030 |
Why?
|
| Ferritins | 1 | 2019 | 597 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2019 | 582 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2004 | 1927 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2003 | 1270 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2022 | 5199 | 0.030 |
Why?
|
| Adolescent Development | 1 | 2020 | 282 | 0.030 |
Why?
|
| Dermatomyositis | 1 | 2019 | 256 | 0.030 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2019 | 732 | 0.030 |
Why?
|
| Drosophila | 1 | 2024 | 1491 | 0.030 |
Why?
|
| Interleukin-6 | 2 | 2020 | 3208 | 0.030 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2014 | 4562 | 0.030 |
Why?
|
| Light | 3 | 1992 | 1345 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 3 | 2007 | 1600 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2021 | 1256 | 0.030 |
Why?
|
| Interleukin-1 | 3 | 1989 | 1249 | 0.030 |
Why?
|
| Triglycerides | 4 | 2004 | 2450 | 0.030 |
Why?
|
| Therapeutics | 1 | 2016 | 113 | 0.030 |
Why?
|
| Models, Economic | 1 | 2020 | 715 | 0.030 |
Why?
|
| Conjunctivitis, Viral | 1 | 1995 | 6 | 0.030 |
Why?
|
| Term Birth | 1 | 2016 | 140 | 0.030 |
Why?
|
| Genomics | 2 | 2023 | 5789 | 0.030 |
Why?
|
| Proteomics | 2 | 2023 | 3816 | 0.030 |
Why?
|
| Language Development Disorders | 1 | 1997 | 192 | 0.030 |
Why?
|
| Photolysis | 1 | 1975 | 94 | 0.030 |
Why?
|
| Social Support | 2 | 2002 | 2153 | 0.030 |
Why?
|
| Conjunctivitis, Bacterial | 1 | 1995 | 22 | 0.030 |
Why?
|
| Hearing | 1 | 1999 | 501 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 8530 | 0.030 |
Why?
|
| Hearing Loss, Sensorineural | 2 | 1992 | 781 | 0.030 |
Why?
|
| Hypotension | 1 | 2021 | 879 | 0.030 |
Why?
|
| Fee-for-Service Plans | 1 | 2000 | 701 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2014 | 10747 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 851 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 9 | 2008 | 7403 | 0.030 |
Why?
|
| Urinary Tract Infections | 1 | 2021 | 812 | 0.030 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2015 | 143 | 0.030 |
Why?
|
| Informed Consent | 1 | 2001 | 1003 | 0.030 |
Why?
|
| Point Mutation | 1 | 2020 | 1593 | 0.030 |
Why?
|
| Pulmonary Circulation | 2 | 2008 | 743 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 6520 | 0.030 |
Why?
|
| Genetic Testing | 2 | 2023 | 3530 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2024 | 2564 | 0.030 |
Why?
|
| Neoplasms | 3 | 2021 | 22030 | 0.030 |
Why?
|
| Dental Care | 1 | 1997 | 279 | 0.030 |
Why?
|
| Speech | 1 | 1999 | 552 | 0.030 |
Why?
|
| Heart Function Tests | 2 | 2007 | 318 | 0.030 |
Why?
|
| Herpesvirus 7, Human | 1 | 1994 | 14 | 0.030 |
Why?
|
| Drug Approval | 1 | 2001 | 809 | 0.030 |
Why?
|
| Anticholesteremic Agents | 1 | 2001 | 963 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2020 | 7590 | 0.030 |
Why?
|
| Fetal Diseases | 1 | 1979 | 911 | 0.030 |
Why?
|
| Parietal Lobe | 1 | 2019 | 849 | 0.030 |
Why?
|
| Thiazoles | 1 | 2021 | 1511 | 0.030 |
Why?
|
| Embolism | 2 | 1998 | 401 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 1997 | 766 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 2019 | 827 | 0.030 |
Why?
|
| Urban Health | 1 | 2016 | 533 | 0.030 |
Why?
|
| Oxygen Consumption | 2 | 2003 | 1846 | 0.030 |
Why?
|
| Video Recording | 1 | 2019 | 954 | 0.030 |
Why?
|
| Awards and Prizes | 1 | 2018 | 359 | 0.030 |
Why?
|
| Rectus Abdominis | 1 | 1994 | 102 | 0.030 |
Why?
|
| Diagnostic Errors | 1 | 2021 | 1263 | 0.030 |
Why?
|
| Diuretics | 1 | 1997 | 610 | 0.030 |
Why?
|
| Cardiac Care Facilities | 1 | 2013 | 34 | 0.030 |
Why?
|
| Propensity Score | 1 | 2021 | 1907 | 0.030 |
Why?
|
| Outpatients | 1 | 2021 | 1591 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 3480 | 0.030 |
Why?
|
| Perfusion | 3 | 2007 | 1374 | 0.030 |
Why?
|
| Genes, Developmental | 1 | 2013 | 38 | 0.030 |
Why?
|
| Competency-Based Education | 1 | 2015 | 218 | 0.030 |
Why?
|
| Half-Life | 2 | 1985 | 652 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2022 | 1740 | 0.030 |
Why?
|
| Writing | 1 | 2015 | 199 | 0.030 |
Why?
|
| Cholesterol, VLDL | 1 | 1993 | 70 | 0.030 |
Why?
|
| P-Selectin | 1 | 1995 | 597 | 0.030 |
Why?
|
| Neutrophils | 2 | 2021 | 3765 | 0.030 |
Why?
|
| GATA4 Transcription Factor | 1 | 2013 | 124 | 0.030 |
Why?
|
| Homozygote | 1 | 2017 | 1788 | 0.030 |
Why?
|
| Immunoassay | 1 | 1996 | 746 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2001 | 1192 | 0.030 |
Why?
|
| Infant Behavior | 1 | 2013 | 154 | 0.030 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2014 | 352 | 0.030 |
Why?
|
| Herpesviridae Infections | 1 | 1994 | 270 | 0.030 |
Why?
|
| Theophylline | 2 | 1984 | 131 | 0.030 |
Why?
|
| Lysophosphatidylcholines | 1 | 1992 | 77 | 0.030 |
Why?
|
| Curriculum | 2 | 2016 | 3717 | 0.030 |
Why?
|
| Psoriasis | 1 | 2000 | 938 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2013 | 473 | 0.030 |
Why?
|
| Particle Size | 1 | 2016 | 1641 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2019 | 2159 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 2021 | 1755 | 0.020 |
Why?
|
| Models, Biological | 8 | 1996 | 9461 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2019 | 4048 | 0.020 |
Why?
|
| Contractile Proteins | 1 | 2012 | 240 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 3 | 1997 | 1911 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2018 | 1141 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 2019 | 1688 | 0.020 |
Why?
|
| Connexins | 1 | 2013 | 351 | 0.020 |
Why?
|
| Creatinine | 2 | 2010 | 1892 | 0.020 |
Why?
|
| Tricuspid Valve | 1 | 2014 | 408 | 0.020 |
Why?
|
| Cardiac Output | 2 | 2005 | 837 | 0.020 |
Why?
|
| Adolescent Behavior | 1 | 2020 | 1184 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2016 | 830 | 0.020 |
Why?
|
| Proxy | 1 | 2012 | 148 | 0.020 |
Why?
|
| Adenine Nucleotides | 1 | 1991 | 111 | 0.020 |
Why?
|
| Vasculitis | 2 | 2005 | 522 | 0.020 |
Why?
|
| Benzopyrans | 1 | 1991 | 63 | 0.020 |
Why?
|
| Metalloendopeptidases | 1 | 2012 | 393 | 0.020 |
Why?
|
| Anthropometry | 2 | 2006 | 1347 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 9405 | 0.020 |
Why?
|
| Spectrophotometry, Infrared | 2 | 2004 | 116 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2021 | 2475 | 0.020 |
Why?
|
| Heterozygote | 1 | 2017 | 2797 | 0.020 |
Why?
|
| House Calls | 1 | 2012 | 160 | 0.020 |
Why?
|
| Salicylates | 1 | 1991 | 127 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2015 | 697 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2021 | 11894 | 0.020 |
Why?
|
| Smad3 Protein | 1 | 2010 | 166 | 0.020 |
Why?
|
| Fasting | 3 | 2006 | 1599 | 0.020 |
Why?
|
| Renal Artery Obstruction | 1 | 1991 | 219 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 1991 | 660 | 0.020 |
Why?
|
| Radiography, Thoracic | 2 | 2010 | 1296 | 0.020 |
Why?
|
| Methylation | 1 | 2013 | 1080 | 0.020 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2010 | 72 | 0.020 |
Why?
|
| T-Lymphocytes | 3 | 2022 | 10171 | 0.020 |
Why?
|
| Medical Records | 1 | 2015 | 1406 | 0.020 |
Why?
|
| Diabetes Complications | 2 | 2007 | 1317 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 4549 | 0.020 |
Why?
|
| Chest Pain | 1 | 2017 | 1090 | 0.020 |
Why?
|
| Dermatitis, Atopic | 2 | 2005 | 716 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 931 | 0.020 |
Why?
|
| Goals | 1 | 2015 | 707 | 0.020 |
Why?
|
| Echocardiography, Stress | 1 | 2010 | 134 | 0.020 |
Why?
|
| Sheep | 2 | 2003 | 1441 | 0.020 |
Why?
|
| Infection Control | 1 | 2017 | 982 | 0.020 |
Why?
|
| Pyridines | 1 | 2021 | 2860 | 0.020 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2010 | 301 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2016 | 1533 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 415 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2023 | 3071 | 0.020 |
Why?
|
| Workload | 1 | 1995 | 847 | 0.020 |
Why?
|
| Measles | 1 | 1991 | 183 | 0.020 |
Why?
|
| Gene Expression | 2 | 2017 | 7583 | 0.020 |
Why?
|
| Decision Making | 1 | 2003 | 3915 | 0.020 |
Why?
|
| Mitochondria | 1 | 2022 | 3584 | 0.020 |
Why?
|
| Prefrontal Cortex | 1 | 2019 | 2209 | 0.020 |
Why?
|
| Lymphocytes | 2 | 1987 | 2610 | 0.020 |
Why?
|
| Cytokines | 1 | 2023 | 7338 | 0.020 |
Why?
|
| Thrombectomy | 1 | 2013 | 690 | 0.020 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2014 | 849 | 0.020 |
Why?
|
| Mitral Valve Prolapse | 2 | 1997 | 214 | 0.020 |
Why?
|
| Pneumonia | 1 | 2020 | 2129 | 0.020 |
Why?
|
| Lysine | 1 | 2013 | 998 | 0.020 |
Why?
|
| Digoxin | 2 | 1979 | 246 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2010 | 437 | 0.020 |
Why?
|
| Uveitis, Anterior | 1 | 1989 | 102 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 1501 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 2014 | 1967 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2010 | 426 | 0.020 |
Why?
|
| Vaccines | 1 | 2017 | 832 | 0.020 |
Why?
|
| Potassium Channels | 1 | 1991 | 534 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 2018 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2020 | 3056 | 0.020 |
Why?
|
| NFATC Transcription Factors | 1 | 2010 | 381 | 0.020 |
Why?
|
| Puberty | 1 | 1991 | 498 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 2551 | 0.020 |
Why?
|
| Emotions | 1 | 2020 | 2734 | 0.020 |
Why?
|
| Conjunctival Diseases | 1 | 1989 | 110 | 0.020 |
Why?
|
| Health Services Research | 2 | 2010 | 1812 | 0.020 |
Why?
|
| Choline | 1 | 2009 | 513 | 0.020 |
Why?
|
| Pharmacokinetics | 1 | 1988 | 86 | 0.020 |
Why?
|
| Penicillins | 2 | 1997 | 406 | 0.020 |
Why?
|
| Students, Medical | 1 | 2001 | 1927 | 0.020 |
Why?
|
| Positron-Emission Tomography | 2 | 2014 | 6457 | 0.020 |
Why?
|
| Serum Albumin | 1 | 1991 | 673 | 0.020 |
Why?
|
| Hyperemia | 1 | 2009 | 221 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 1983 | 4217 | 0.020 |
Why?
|
| Cholesterol | 2 | 1998 | 2901 | 0.020 |
Why?
|
| Biological Availability | 2 | 1985 | 390 | 0.020 |
Why?
|
| Rewarming | 1 | 2007 | 64 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1992 | 1446 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2010 | 23341 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 2009 | 576 | 0.020 |
Why?
|
| Irritable Mood | 1 | 2008 | 194 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2012 | 1133 | 0.020 |
Why?
|
| Lymphatic Diseases | 1 | 1989 | 319 | 0.020 |
Why?
|
| Catheterization | 1 | 1992 | 1426 | 0.020 |
Why?
|
| Teaching | 1 | 2015 | 1168 | 0.020 |
Why?
|
| Neonatology | 1 | 2009 | 140 | 0.020 |
Why?
|
| Infant Mortality | 1 | 2012 | 757 | 0.020 |
Why?
|
| Radioimmunoassay | 2 | 1988 | 866 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 2007 | 203 | 0.020 |
Why?
|
| E-Selectin | 3 | 1995 | 576 | 0.020 |
Why?
|
| Health Care Rationing | 1 | 2010 | 434 | 0.020 |
Why?
|
| Oral Hygiene | 2 | 1997 | 129 | 0.020 |
Why?
|
| Animals, Newborn | 2 | 2003 | 2673 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2014 | 1718 | 0.020 |
Why?
|
| Dentistry | 2 | 1997 | 117 | 0.020 |
Why?
|
| Solubility | 4 | 1984 | 1087 | 0.020 |
Why?
|
| Appetite | 1 | 2008 | 247 | 0.020 |
Why?
|
| Retroviridae Infections | 1 | 1987 | 146 | 0.020 |
Why?
|
| Sleep | 1 | 2022 | 4745 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2013 | 1356 | 0.020 |
Why?
|
| Lymphocyte Activation | 2 | 2007 | 5490 | 0.020 |
Why?
|
| Pulmonary Heart Disease | 1 | 1986 | 34 | 0.020 |
Why?
|
| Comprehension | 1 | 2011 | 619 | 0.020 |
Why?
|
| Guatemala | 1 | 2006 | 159 | 0.020 |
Why?
|
| Office Visits | 1 | 2010 | 596 | 0.020 |
Why?
|
| Enterohepatic Circulation | 1 | 1985 | 12 | 0.020 |
Why?
|
| Fingers | 1 | 2009 | 506 | 0.020 |
Why?
|
| Body Weight | 1 | 2016 | 4603 | 0.020 |
Why?
|
| Neopterin | 1 | 2005 | 56 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2014 | 9266 | 0.020 |
Why?
|
| Muscle Weakness | 1 | 2008 | 413 | 0.020 |
Why?
|
| Self Report | 1 | 2017 | 3712 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2016 | 2976 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 2189 | 0.020 |
Why?
|
| Vomiting | 1 | 2008 | 651 | 0.020 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2011 | 606 | 0.020 |
Why?
|
| Models, Chemical | 3 | 1988 | 610 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 3615 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 1985 | 361 | 0.020 |
Why?
|
| Physical Examination | 1 | 1991 | 1244 | 0.020 |
Why?
|
| Education, Medical | 1 | 2016 | 1725 | 0.020 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2010 | 570 | 0.020 |
Why?
|
| Diet | 3 | 1982 | 8003 | 0.020 |
Why?
|
| Hospital Charges | 2 | 1998 | 357 | 0.020 |
Why?
|
| Cough | 1 | 2008 | 594 | 0.010 |
Why?
|
| Recurrence | 2 | 2014 | 8426 | 0.010 |
Why?
|
| Heart Rate | 2 | 2015 | 4166 | 0.010 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 996 | 0.010 |
Why?
|
| Leukocyte Elastase | 1 | 2005 | 114 | 0.010 |
Why?
|
| Pyrroles | 1 | 1991 | 1130 | 0.010 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2005 | 169 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 4106 | 0.010 |
Why?
|
| Mexican Americans | 1 | 2005 | 165 | 0.010 |
Why?
|
| Arthralgia | 1 | 2008 | 461 | 0.010 |
Why?
|
| Lipocalins | 1 | 2005 | 161 | 0.010 |
Why?
|
| Protons | 1 | 2009 | 1112 | 0.010 |
Why?
|
| Rats, Inbred Strains | 3 | 1992 | 2090 | 0.010 |
Why?
|
| Acute-Phase Proteins | 1 | 2005 | 250 | 0.010 |
Why?
|
| Dietary Fats | 1 | 1992 | 1991 | 0.010 |
Why?
|
| Drinking | 1 | 2005 | 199 | 0.010 |
Why?
|
| Rats | 6 | 1992 | 23681 | 0.010 |
Why?
|
| Receptors, IgE | 1 | 2005 | 372 | 0.010 |
Why?
|
| Oxyhemoglobins | 1 | 2004 | 212 | 0.010 |
Why?
|
| Staphylococcal Infections | 2 | 2003 | 1406 | 0.010 |
Why?
|
| Muscle, Skeletal | 2 | 1995 | 4902 | 0.010 |
Why?
|
| Delivery of Health Care | 2 | 2013 | 5331 | 0.010 |
Why?
|
| Urine | 1 | 2005 | 363 | 0.010 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 1526 | 0.010 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2010 | 833 | 0.010 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2005 | 218 | 0.010 |
Why?
|
| Castration | 1 | 1983 | 153 | 0.010 |
Why?
|
| Aneurysm | 1 | 1986 | 336 | 0.010 |
Why?
|
| Immunoglobulin E | 2 | 2005 | 1484 | 0.010 |
Why?
|
| Pulmonary Alveoli | 1 | 1986 | 651 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2011 | 4624 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 1992 | 2201 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 1997 | 18125 | 0.010 |
Why?
|
| Veins | 1 | 1986 | 765 | 0.010 |
Why?
|
| Reperfusion Injury | 2 | 2003 | 1022 | 0.010 |
Why?
|
| Sodium | 2 | 2005 | 1588 | 0.010 |
Why?
|
| Divorce | 1 | 1982 | 76 | 0.010 |
Why?
|
| Genes, jun | 1 | 2002 | 68 | 0.010 |
Why?
|
| Developing Countries | 1 | 2015 | 2866 | 0.010 |
Why?
|
| Diarrhea | 1 | 2008 | 1317 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 5779 | 0.010 |
Why?
|
| Genes, fos | 1 | 2002 | 174 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1992 | 1539 | 0.010 |
Why?
|
| Papio | 1 | 1983 | 661 | 0.010 |
Why?
|
| Pressure | 1 | 2004 | 1155 | 0.010 |
Why?
|
| Siblings | 1 | 2005 | 824 | 0.010 |
Why?
|
| Protein Binding | 2 | 2010 | 9312 | 0.010 |
Why?
|
| Adolescent Medicine | 1 | 2001 | 73 | 0.010 |
Why?
|
| Immunotherapy | 1 | 1997 | 4641 | 0.010 |
Why?
|
| Epilepsy | 2 | 1993 | 3269 | 0.010 |
Why?
|
| Enterococcus | 1 | 2002 | 160 | 0.010 |
Why?
|
| Rhinitis | 1 | 2008 | 746 | 0.010 |
Why?
|
| Transducers | 1 | 1982 | 240 | 0.010 |
Why?
|
| Eosinophilia | 1 | 2005 | 559 | 0.010 |
Why?
|
| Brain Edema | 1 | 2005 | 603 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2002 | 506 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 2004 | 664 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 1993 | 3047 | 0.010 |
Why?
|
| Mice | 2 | 2020 | 81107 | 0.010 |
Why?
|
| Oxacillin | 1 | 1979 | 41 | 0.010 |
Why?
|
| Aged | 6 | 2021 | 168217 | 0.010 |
Why?
|
| Beverages | 1 | 2005 | 818 | 0.010 |
Why?
|
| Ions | 2 | 1977 | 256 | 0.010 |
Why?
|
| Auditory Perception | 1 | 1984 | 580 | 0.010 |
Why?
|
| Administration, Oral | 2 | 1988 | 3993 | 0.010 |
Why?
|
| Sulfasalazine | 1 | 1979 | 84 | 0.010 |
Why?
|
| Glycoproteins | 1 | 1986 | 2205 | 0.010 |
Why?
|
| Immediate-Early Proteins | 1 | 2002 | 449 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2002 | 906 | 0.010 |
Why?
|
| Heart Atria | 2 | 1995 | 1344 | 0.010 |
Why?
|
| Enteral Nutrition | 1 | 2004 | 785 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2009 | 3527 | 0.010 |
Why?
|
| Fungemia | 1 | 1998 | 58 | 0.010 |
Why?
|
| Cadaver | 1 | 1983 | 1345 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2004 | 1519 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2012 | 6201 | 0.010 |
Why?
|
| Fee Schedules | 1 | 1998 | 85 | 0.010 |
Why?
|
| Disease Susceptibility | 2 | 1997 | 1788 | 0.010 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 1977 | 200 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2005 | 981 | 0.010 |
Why?
|
| Ascites | 1 | 1979 | 338 | 0.010 |
Why?
|
| Streptococcal Infections | 1 | 2002 | 617 | 0.010 |
Why?
|
| Erythromycin | 1 | 1997 | 117 | 0.010 |
Why?
|
| MEDLINE | 1 | 1997 | 119 | 0.010 |
Why?
|
| Methanol | 1 | 1977 | 91 | 0.010 |
Why?
|
| Photochemistry | 1 | 1977 | 239 | 0.010 |
Why?
|
| Life Tables | 1 | 1997 | 365 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 1055 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2005 | 1815 | 0.010 |
Why?
|
| Medicare Part B | 1 | 1998 | 117 | 0.010 |
Why?
|
| Clindamycin | 1 | 1997 | 140 | 0.010 |
Why?
|
| Cardiomegaly | 1 | 1979 | 591 | 0.010 |
Why?
|
| Perinatal Care | 1 | 1999 | 242 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 2816 | 0.010 |
Why?
|
| Amoxicillin | 1 | 1997 | 180 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2007 | 3997 | 0.010 |
Why?
|
| Ethics, Medical | 1 | 2001 | 783 | 0.010 |
Why?
|
| Pancreas | 1 | 1983 | 1676 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 58681 | 0.010 |
Why?
|
| Health Occupations | 1 | 1977 | 222 | 0.010 |
Why?
|
| Caffeine | 1 | 1980 | 701 | 0.010 |
Why?
|
| Acetylcholine | 1 | 1977 | 628 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2005 | 3441 | 0.010 |
Why?
|
| Pulmonary Medicine | 1 | 1997 | 221 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4567 | 0.010 |
Why?
|
| Cells, Cultured | 4 | 1995 | 18942 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 22006 | 0.010 |
Why?
|
| Bacteria | 1 | 2005 | 2199 | 0.010 |
Why?
|
| Computer-Assisted Instruction | 1 | 1977 | 362 | 0.010 |
Why?
|
| Antigens, Surface | 2 | 1989 | 1607 | 0.010 |
Why?
|
| Skin | 3 | 1995 | 4464 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 1980 | 2359 | 0.010 |
Why?
|
| Cineangiography | 1 | 1992 | 112 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 4485 | 0.010 |
Why?
|
| Reimbursement Mechanisms | 1 | 1998 | 663 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1992 | 374 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1977 | 1745 | 0.010 |
Why?
|
| Chromatography | 1 | 1992 | 189 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 1998 | 1673 | 0.010 |
Why?
|
| Glucose | 1 | 2004 | 4336 | 0.010 |
Why?
|
| Bone Conduction | 1 | 1992 | 102 | 0.010 |
Why?
|
| Audiometry, Pure-Tone | 1 | 1992 | 210 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2003 | 2629 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2006 | 3432 | 0.010 |
Why?
|
| Oral Health | 1 | 1997 | 486 | 0.010 |
Why?
|
| Bronchoscopy | 1 | 1997 | 910 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1995 | 1900 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1992 | 416 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1995 | 2263 | 0.010 |
Why?
|
| Cromakalim | 1 | 1991 | 22 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1977 | 2222 | 0.010 |
Why?
|
| Gynecology | 1 | 1997 | 528 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2006 | 3755 | 0.010 |
Why?
|
| Ultrafiltration | 1 | 1991 | 49 | 0.010 |
Why?
|
| Auditory Threshold | 1 | 1992 | 369 | 0.010 |
Why?
|
| Histocompatibility | 1 | 1992 | 316 | 0.010 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1992 | 303 | 0.010 |
Why?
|
| Phosphatidylcholines | 1 | 1992 | 405 | 0.010 |
Why?
|
| Gastroenterology | 1 | 1997 | 571 | 0.010 |
Why?
|
| Scattering, Radiation | 1 | 1992 | 488 | 0.010 |
Why?
|
| Macrophages | 1 | 2005 | 5737 | 0.010 |
Why?
|
| Aging | 2 | 2007 | 8651 | 0.010 |
Why?
|
| Obstetrics | 1 | 1997 | 667 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1991 | 613 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 12436 | 0.010 |
Why?
|
| Hearing Tests | 1 | 1990 | 121 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 1991 | 557 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1990 | 395 | 0.010 |
Why?
|
| Graft Rejection | 1 | 1983 | 4426 | 0.010 |
Why?
|
| HLA-DQ Antigens | 1 | 1989 | 211 | 0.010 |
Why?
|
| Absorption | 1 | 1988 | 243 | 0.000 |
Why?
|
| Endoscopy | 1 | 1997 | 1834 | 0.000 |
Why?
|
| Liver | 1 | 1983 | 7502 | 0.000 |
Why?
|
| Deltaretrovirus | 1 | 1986 | 161 | 0.000 |
Why?
|
| Feeding Behavior | 1 | 1979 | 3183 | 0.000 |
Why?
|
| Dipyridamole | 1 | 1986 | 141 | 0.000 |
Why?
|
| Immunoglobulin A | 1 | 1990 | 979 | 0.000 |
Why?
|
| Circadian Rhythm | 1 | 1978 | 2567 | 0.000 |
Why?
|
| Eczema | 1 | 1988 | 245 | 0.000 |
Why?
|
| Ovariectomy | 1 | 1988 | 610 | 0.000 |
Why?
|
| Immunoglobulin M | 1 | 1990 | 1529 | 0.000 |
Why?
|
| Membrane Proteins | 1 | 2002 | 7843 | 0.000 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1986 | 272 | 0.000 |
Why?
|
| Biometry | 1 | 1988 | 559 | 0.000 |
Why?
|
| Autoimmunity | 1 | 1992 | 1358 | 0.000 |
Why?
|
| Neck | 1 | 1989 | 731 | 0.000 |
Why?
|
| Membranes | 1 | 1984 | 165 | 0.000 |
Why?
|
| Lung | 1 | 2003 | 9985 | 0.000 |
Why?
|
| Endothelium | 1 | 1986 | 764 | 0.000 |
Why?
|
| Retroviridae | 1 | 1986 | 850 | 0.000 |
Why?
|
| Ampicillin | 1 | 1984 | 141 | 0.000 |
Why?
|
| Manganese | 1 | 1986 | 395 | 0.000 |
Why?
|
| Tablets | 1 | 1984 | 147 | 0.000 |
Why?
|
| Capsules | 1 | 1984 | 191 | 0.000 |
Why?
|
| Receptors, Immunologic | 1 | 1989 | 1411 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1986 | 2557 | 0.000 |
Why?
|
| Intestinal Absorption | 1 | 1984 | 400 | 0.000 |
Why?
|
| Cell Adhesion | 1 | 1989 | 3090 | 0.000 |
Why?
|
| Magnesium | 1 | 1986 | 809 | 0.000 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1990 | 1826 | 0.000 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 12076 | 0.000 |
Why?
|
| Membranes, Artificial | 1 | 1984 | 366 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1992 | 6068 | 0.000 |
Why?
|
| Medicare | 1 | 2000 | 6741 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 1995 | 11070 | 0.000 |
Why?
|
| Dioxanes | 1 | 1980 | 36 | 0.000 |
Why?
|
| Hot Temperature | 1 | 1986 | 1434 | 0.000 |
Why?
|
| Energy Metabolism | 1 | 1991 | 2868 | 0.000 |
Why?
|
| Vascular Resistance | 1 | 1982 | 930 | 0.000 |
Why?
|
| Saliva | 1 | 1984 | 820 | 0.000 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 1980 | 275 | 0.000 |
Why?
|
| New England | 1 | 1982 | 1053 | 0.000 |
Why?
|
| Solvents | 1 | 1980 | 292 | 0.000 |
Why?
|
| Membrane Glycoproteins | 1 | 1989 | 3705 | 0.000 |
Why?
|
| Naphthalenes | 1 | 1979 | 198 | 0.000 |
Why?
|
| Polyethylene Glycols | 1 | 1984 | 1188 | 0.000 |
Why?
|
| Monocytes | 1 | 1986 | 2570 | 0.000 |
Why?
|
| Cell Survival | 1 | 1986 | 5781 | 0.000 |
Why?
|
| Models, Theoretical | 1 | 1988 | 3561 | 0.000 |
Why?
|
| Guinea Pigs | 1 | 1977 | 1317 | 0.000 |
Why?
|
| Ileum | 1 | 1977 | 555 | 0.000 |
Why?
|
| Biopsy | 1 | 1986 | 6768 | 0.000 |
Why?
|
| Cell Line | 1 | 1986 | 15594 | 0.000 |
Why?
|